高级检索
当前位置: 首页 > 详情页

MicroRNA-125b protects hyperglycemia-induced, human retinal pigment epithelial cells (RPE) from death by targeting hexokinase 2

| 认领 | 导出 |

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

单位: [1]Department of Ophthalmology, 307 Hospital of PLA, Beijing, China [2]Department of Ophthalmology, China-Japan Friendship Hospital, Beijing, China
出处:
ISSN:

关键词: Diabetic retinal disease microRNA-125b retinal pigment epithelial cells hexokinase 2

摘要:
Diabetic retinal disease (DR) is the main cause of visual disability and blindness in adults with diabetes mellitus. Currently, efficient prevention and treatment are still under investigation. MicroRNAs (miRNAs) are groups of short, non-coding RNAs that post-transcriptionally control their target genes' expression through complementary binding to the 3'UTR region. MiRNAs have been reported to play important roles in a variety of physiological and pathophysiological processes. However, the roles of miR-125b in DR are still unclear. In this study, we exposed human retinal pigment epithelial (RPE) cells to high glucose levels to mimic DR progression. Hyperglycemia induced RPE cell death in 1, 3 and 5 days. Meanwhile, we observed that miR-125b expressions were significantly downregulated by the high glucose treatments. We demonstrated elevated cellular glycolysis rates of RPE cells under hyperglycemia. The glycolysis key enzymes, GLUT1, Hexokinase 2 (HK2) and LDHA were upregulated by high glucose. Moreover, treatments of RPE cells with low-toxic dosages of the glycolysis inhibitor, 2-DG or Oxamate, rescued the high glucose-induced cell from death. We identified hexokinase 2 as a direct target of miR-125b in RPE cells by showing the binding of the miR-125b seed region to HK2 mRNA 3'UTR. Notably, we demonstrated that the overexpression of miR-125b significantly attenuated hyperglycemia-induced RPE cell death. This study reveals a new mechanism for miRNA-mediated cellular protection against RPE cell death, representing an effective DR-treatment approach.

基金:
语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学 4 区 病理学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学 4 区 病理学
JCR分区:
出版当年[2016]版:
Q3 PATHOLOGY Q4 ONCOLOGY
最新[2023]版:
Q3 PATHOLOGY Q4 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2016版] 出版当年五年平均[2012-2016] 出版前一年[2015版] 出版后一年[2017版]

第一作者:
第一作者单位: [1]Department of Ophthalmology, 307 Hospital of PLA, Beijing, China
通讯作者:
通讯机构: [2]Department of Ophthalmology, China-Japan Friendship Hospital, Beijing, China [*1]Department of Ophthalmology, China-Japan Friendship Hospital, 2 Yinghua Dongjie, Hepingli, Beijing 100029, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:816 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)